Head of Investor Relations
Acadia Pharmaceuticals Inc (ACAD)Equibles does not estimate personal net worth.
Mark Johnson is recorded as Head of Investor Relations at Acadia Pharmaceuticals Inc (ACAD). Mark Johnson has spoken on 12 earnings calls across 1 company, most recently for Acadia Pharmaceuticals Inc on May 8, 2023. Acadia Pharmaceuticals Inc is classified in the Biotechnology industry within the Healthcare sector. Other leadership on record at Acadia Pharmaceuticals Inc includes Catherine Owen Adams (CEO and Board Member), Stephen R. Biggar (Chairman and Board Member), Mark C. Schneyer (CFO) and 7 others.
“Good afternoon and thank you for joining us on today's call to discuss ACADIA's first quarter 2023 financial results.”
“And thank you for joining us on today’s call to discuss ACADIA’s fourth quarter and full year 2022 financial results.”
“Good afternoon, and thank you for joining us on today's call to discuss ACADIA's third quarter 2022 financial results.”
“Good afternoon, and thank you for joining us on today's call of ACADIA's Second Quarter 2020 Financial Results.”
“Good afternoon and thank you for joining us on today's call to discuss Acadia's first quarter 2022 financial results. Joining me on the call today from ACADIA are Steve Davis, our Chief Executive Officer who will provide an overview of our first quarter performance and a review of our business.”
Biotechnology · Healthcare
Head of Investor Relations
